MedPath
HSA Approval

MUCODIN SYRUP 250 mg/5 ml

SIN03003P

MUCODIN SYRUP 250 mg/5 ml

MUCODIN SYRUP 250 mg/5 ml

May 31, 1989

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSUNWARD PHARMACEUTICAL PRIVATE LIMITED
Licence HolderSUNWARD PHARMACEUTICAL PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R05CB03

carbocisteine

Manufacturer Information

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL SDN BHD

Active Ingredients

CARBOCISTEINE

250 mg/5 ml

Carbocisteine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

MUCODIN SYRUP 250 mg/5 ml - HSA Approval | MedPath